Mohamed Shouman

Dr. Mohamed Shouman


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 January 2024 in Clinical and Translational Radiation Oncology
Verified
Journal Article
Open access
MSMohamed Shouman
Mohamed Shouman
FFFrederik Fuchs
Frederik Fuchs
FWFranziska Walter
Franziska Walter
SCStefanie Corradini
Stefanie Corradini
CWC Benedikt Westphalen
C Benedikt Westphalen
PRPaul Rogowski
Paul Rogowski
This systematic review aims to comprehensively summarize the current prospective evidence regarding Stereotactic Body Radiotherapy (SBRT) in various clinical contexts for pancreatic cancer including its use as neoadjuvant therapy for borderline resectable pancreatic cancer (BRPC), induction therapy for locally advanced pancreatic cancer (LAPC), salvage therapy for isolated local recurrence (ILR), adjuvant therapy after radical resection, and as a palliative treatment. Special attention is given to the application of magnetic resonance-guided radiotherapy (MRgRT). Following PRISMA guidelines, a systematic review of the Medline database via PubMed was conducted focusing on prospective studies published within the past decade. Data were extracted concerning study characteristics, outcome measures, toxicity profiles, SBRT dosage and fractionation regimens, as well as additional systemic therapies. 31 studies with in total 1,571 patients were included in this review encompassing 14 studies for LAPC, 9 for neoadjuvant treatment, 2 for adjuvant treatment, 2 for ILR, with an additional 4 studies evaluating MRgRT. In LAPC, SBRT demonstrates encouraging results, characterized by favorable local control rates. Several studies even report conversion to resectable disease with substantial resection rates reaching 39%. The adoption of MRgRT may provide a solution to the challenge to deliver ablative doses while minimizing severe toxicities. In BRPC, select prospective studies combining preoperative ablative-dose SBRT with modern induction systemic therapies have achieved remarkable resection rates of up to 80%. MRgRT also holds potential in this context. Adjuvant SBRT does not appear to confer relevant advantages over chemotherapy. While prospective data for SBRT in ILR and for palliative pain relief are limited, they corroborate positive findings from retrospective studies.

20 November 2025 in Technical Innovations & Patient Support in Radiation Oncology
Verified
Journal Article
Open access
DKDinah Konnerth
Dinah Konnerth
HHHidehiro Hojo
Hidehiro Hojo
FFFrederik Fuchs
Frederik Fuchs
MSMohamed Shouman
Mohamed Shouman
DDDiana-Coralia Dehelean
Diana-Coralia Dehelean
PRPaul Rogowski
Paul Rogowski
Ablative stereotactic radiotherapy for pancreatic ductal adenocarcinoma (PDAC) is limited by adjacent radiosensitive organs at risk (OAR) that exhibit significant daily positional variability. This study aims to investigate the benefit of stereotactic MRI-guided online adaptive radiotherapy (SMART) with elective fields on target coverage and OAR dose sparing in patients with PDAC. We retrospectively analysed 62 consecutive PDAC patients treated with SMART between 2020–2024, totaling 310 fractions. For each fraction, a non-adapted plan (PLANPREDICT) was compared to its online-adapted counterpart (PLANREOPTIMIZED). We assessed planning target volume (PTV) coverage and OAR constraints. Plan-adaptation was classified as “useful” when the PLANREOPTIMIZED met all objectives or improved PTV coverage or OAR sparing by ≥ 10 %, as “futile” when PLANREOPTIMIZED failed to meet or markedly improve objectives, and as “not necessary” when PLANPREDICT already met all objectives. Prescribed doses were 40 Gy (71 %) and 33 Gy (29 %) over five fractions. A simultaneous integrated boost approach was used in 47 % of patients. The PLANPREDICT met all planning goals in 1 % of fractions, which increased to 72 % with PLANREOPTIMIZED. Adaptation yielded significant improvements in PTV coverage (p < 0.001) and reductions in V33Gy for stomach (median 0.26 cc vs. 0.01 cc), duodenum (median 1.08 cc vs. 0.07 cc) and bowel (median 2.04 cc vs. 0.06 cc), all p < 0.001. Adaptation was deemed useful in 305 (98 %), not necessary in 4 (1 %) and futile in 1 fraction (0.3 %). For the vast majority of PDAC patients treated with stereotactic radiotherapy with elective fields daily online adaptation enhances target coverage and OAR sparing.